What is MTVA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for MTVA?

P/E (TTM) is n/a and 52-week range is $0.97 to $14.85 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s MTVA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for MTVA?

The company profile lists net income (TTM) near $-21M, EPS (TTM) near $-4.05 when available from the market-data feed. Figures are informational and may lag live markets.

Where is MetaVia Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Cambridge, Massachusetts, US, 5.2M shares outstanding, ISIN US64132R5037 when available from company profile and filing metadata.

MetaVia Inc

$MTVA

Health Care · Biotechnology

IR Run Scenarios

$1.41

+5.22%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2016-08-05. The company is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.

Employees

Website

metaviatx.com/

IPO

2016-08-05

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)